Deal Watch: Bristol Continues Push Into Fibrotic Disease Area
Executive Summary
Novartis and Amgen exchange rights around CNS candidates in Alzheimer’s and migraine. AstraZeneca out-licenses global rights, except for Japan and Asia, for Phase III psoriasis candidate brodalumab to Valeant.